Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atrial switch

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Atrial switch. Displaying page 1 of 1.
    EudraCT Number: 2006-006863-22 Sponsor Protocol Number: 2006/CD/013 Start Date*: 2007-09-24
    Sponsor Name:University Hospital of South Manchester NHS Foundation Trust
    Full Title: Role of Poly Unsaturated Fatty Acids (PUFAs) in the management of Paroxysmal Atrial Fibrillation (PAF)
    Medical condition: Paroxysmal Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10034039 Paroxysmal atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000055-41 Sponsor Protocol Number: CV185-220 Start Date*: 2013-08-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
    Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003677-33 Sponsor Protocol Number: 7210 Start Date*: 2018-02-02
    Sponsor Name:Leiden University Medical Center
    Full Title: The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study
    Medical condition: patients who are diagnosed with atrial fibrillation or venous thrombosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000481-14 Sponsor Protocol Number: APHP210166 Start Date*: 2021-12-20
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Cardiometabolic effects of dapagliflozin in heart failure with reduced ejection fraction: an exploratory study.
    Medical condition: Heart failure with reduced ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003894-26 Sponsor Protocol Number: 1160.26 Start Date*: 2005-12-23
    Sponsor Name:Boehringer Ingelheim AB
    Full Title: Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke...
    Medical condition: Prevention of Stroke and Systemic Embolism in patients with Atrial Fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) CZ (Completed) AT (Completed) HU (Completed) DE (Completed) SK (Completed) IT (Completed) ES (Completed) GB (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000393-11 Sponsor Protocol Number: NL60426 Start Date*: 2017-09-07
    Sponsor Name:University Medical Center utrecht
    Full Title: ’Switching anticoagulant management from a VKA to a NOAC-based treatment strategy in frail elderly patients with atrial fibrillation (FRAIL-AF study)
    Medical condition: Atrial Fibrilation
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004291-21 Sponsor Protocol Number: 33IC30_166855 Start Date*: 2018-01-15
    Sponsor Name:Insel Gruppe AG - Inselspital Universitätsklinik für Kardiologie
    Full Title: Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function – a multi-center, double-blind, randomized, placebo-controlled clinical trial – SERVE Trial
    Medical condition: Adults with congenital heart disease (CHD) and a right ventricle (RV) in subaortic (systemic) position.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001845-15 Sponsor Protocol Number: TINCRBEL_study Start Date*: 2018-07-13
    Sponsor Name:Academic medical centre, department of internal medicine
    Full Title: EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study)
    Medical condition: Chronic intestinal failuyre (IF) is caused by large surgical bowel resection, severe motility, or absorption diseorders. These patientds require partial or total parenteral nutrition (PN and TPN, r...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002605-53 Sponsor Protocol Number: EVEDES Start Date*: 2008-05-20
    Sponsor Name:Fundació Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau
    Full Title: Antagonistas aldosterónicos en el tratamiento de pacientes con ventrículo derecho sistémico: ensayo clínico aleatorizado.
    Medical condition: Transposición de grandes vasos tratada mediante la técnica de redirección auricular (técnicas de Senning o Mustard).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010143 Complete transposition of great vessels LLT
    9.1 10044443 Transposition of the great vessels LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005223-90 Sponsor Protocol Number: PULSE-PAH-004 Start Date*: 2016-07-12
    Sponsor Name:Bellerophon Pulse Technologies LLC
    Full Title: A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (iNO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS W...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) AT (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018322-40 Sponsor Protocol Number: AC-066A301 Start Date*: 2010-05-20
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 20:09:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA